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Abstract: Colorectal cancer is the leading cause of cancer related deaths in the United States. Although it is preventable, 
thousands of lives are lost each year in the U.S. to colorectal cancer than to breast cancer and AIDS combined. In colon 
cancer, the formation and progression of precancerous lesions like aberrant crypt foci and polyps is associated with the up-
regulation of cycloxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS) and hydroxy methyl glutaryl CoA reductase 
(HMG-CoA reductase). The current review will focus on the signaling pathway involving COX-2 and HMG-CoA reductase 
enzymes and their downstream effectors in signaling mechanism. Cancer cells need huge pools of both cholesterol and 
isoprenoids to sustain their unlimited growth potential. Cholesterol by modulating caveolae formation regulates several 
signaling molecules like AKT, IGFR, EGFR and Rho which are involved in cell growth and survival. Cholesterol is also 
essential for lipid body formation which serves as storage sites for COX-2, eicosanoids and caveolin-1. Experimental stud-
ies have identiﬁ  ed important mechanisms showing that COX-2, caveolin-1, lipid bodies and prenylated proteins is involved 
in carcinogenesis. Therefore multi-target, multi-drug approach is the ideal choice for effective colon cancer chemopreven-
tion. This review will give an overview of the two pathways, their signaling networks, and the interactions between the 
components of the two networks in the activation and regulation of cell signaling involving growth/survival and explain the 
rationale for colon cancer chemoprevention using COX-2 inhibitors and statins.
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Introduction
The systems biology approach to gene regulation involves the study of networks of genes between 
well-characterized pathways. However, the fundamental challenge is to predict how a certain drug 
interacts with the cellular and molecular components of the signaling network. This will help in under-
standing the expected behavior of a drug interaction with the signaling network. The interaction will 
then guide the behavior of the cell. Therefore, the identiﬁ  cation of the signaling network or crosstalk 
among various signal pathways is of fundamental importance in developing novel strategies for preven-
tion and treatment of cancer. Comparative analysis of these networks is central to our understanding of 
the biological systems.
Today, our knowledge and technology have reached a point where it is possible to identify individuals 
at risk for cancer and disrupt the processes at the level of the pre-cancerous lesion thereby blocking the 
neoplastic transformation and ultimately metastasis. Understanding the systems biology of colonic pre-
neoplasia and progression to adenoma and adenocarcinoma enhances the likelihood of designing novel 
chemoprevention strategies for prevention of colon cancer. The current review will focus on targeting 
multiple pathways for colon cancer chemoprevention. The underlying basis of many cancers is due to 
defective regulation of signaling pathways that control cellular proliferation and differentiation. It is now 
thought that normal self-renewing stem cells that persist throughout life become tumorigenic as a result 
of accumulated mutations and the transforming events that lead to dysregulation of their metabolic path-
ways. Understanding the differences between the cross-talk that occurs in normal cells, and the cross-talk 
that occurs in cancer cells will provide insight that could lead to new strategies for treating cancer.
Signiﬁ  cance of Colorectal Cancer
Colorectal cancer is one of the leading causes of cancer related death in the western world, including 
the United States. The American Cancer Society estimates that about 112,340 new cases of colon cancer 164
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(55,290 men and 57,050 women) and 41,420 new 
cases of rectal cancer (23,840 men and 17,580 
women) will be diagnosed in the United States in 
2007. It is the second leading cause of cancer-
related deaths with 52,180 deaths (26,000 men and 
26,180 women) expected during 2007 (American 
Cancer Society, 2007). The costs from hospitaliza-
tion are much more among colorectal cancer 
patients than among lung, prostrate and breast 
cancer patients. Most colorectal cancers start as 
non-cancerous polyps, some of which progress in 
size to form large polyps (1.0 cm), and then to 
adenoma and carcinoma (Janne and Mayer, 2000, 
Fig. 1). Since colorectal cancers develop slowly 
over a long period, which is at least ten years in 
most people (Smith et al. 2001), chemoprevention 
can be used to control colon cancer progression. 
The data from human and animal models show that 
the etiology of colon cancer is multifactorial and 
complex. As a result, increasing efforts are being 
focused on developing more effective screening 
and prevention measures for colorectal cancer. A 
major area of research emphasis is the inverse 
relationship between certain biochemical pathways 
and the development of cancer. A number of 
metabolic pathways or individual molecules are 
upregulated in colon cancer. The current review 
will focus on the upregulation of COX-2 and 
HMG-CoA reductase enzymes and the signaling 
cascades that are altered as a result of this 
up-regulation.
Under normal physiologic circumstances, 
COX-2 is expressed in the GI tract at undetectable 
levels. But, this expression rises signiﬁ  cantly in 
inflammation and colorectal malignancies 
(Kutchera et al. 1996; Kargman et al. 1996). For 
example, COX-2 is up-regulated 2 to 50-fold in 
85% to 90% of colorectal tumors, making the 
COX-2 enzyme a good target candidate for che-
moprevention (Eberhart CE, 1994). The observa-
tion that HMG-CoA reductase is upregulated in 
colon cancer came from two large clinical trials 
designed to study the changes in coronary events 
in coronary heart disease. In patients receiving 
HMG-CoA reductase inhibitors (pravastatin, 
simvastatin), the number of newly diagnosed colon 
cancer cases reduced by 43% and 19% during a 
5-year follow-up period (Sacks et al. 1996; Pedersen 
et al. 1996). A thorough understanding of the differ-
ences between altered signaling pathways in cancer 
cells and the signaling pathways in normal cells will 
lead to the design of new therapeutic strategies for 
Figure 1. Colon cancer progression and overexpression of stage speciﬁ  c markers.
Colon cancer are originated from hyperproliferative regions in the normal colonic mucosa as polyps that develop into adenoma and ﬁ  nally 
carcinoma. The adenoma-carcinoma sequence is characterized by overexpression of several markers like COX-2, HMG-CoA-R, AKT and 
caveolin-1. Intervention of colon cancer progression can be achieved by using various chemopreventive agents either alone or in combination 
(modiﬁ  ed from Janne and Mayer. 2000. New Engl J Med.)165
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suppressing the tumorigenic and invasive potential 
of malignant tumors.
COX-2 and Colon Cancer
COX is a bifunctional enzyme that sequentially 
catalyzes cyclooxygenase and peroxidase reactions 
(Smith et al. 1991). It is a membrane-bound heme-
protein that catalyzes the bisoxygenation of ara-
chidonic acid (a fatty substance) to form 
prostaglandin PGG2 and the peroxidative reduction 
of PGG2 to form prostaglandin PGH2 (Smith et al. 
1991). Prostaglandins are hormone-like substances 
found in very small quantities in the body which 
have potent physiological effects. There are two 
structural forms of cyclooxygenase, COX-1 
(Cycloxygenase 1) and COX-2 (Smith et al. 
2000). COX-1 was identiﬁ  ed in 1976 (Hemler 
et al. 1976; Miyamoto et al. 1976) and cloned a 
decade later by three different groups (Merlie 
et al. 1988; DeWitt, 1988; Yokoyama et al. 1989). 
Cyclooxygenase-1 (COX-1) is an enzyme which 
is normally present in a several areas of the body, 
including sites of inﬂ  ammation and the stomach. 
COX-1 primarily serves a maintenance function 
with stable levels, while the gene for COX-2 is 
inducible, or stimulated by growth factors, cyto-
kines, carcinogens, oncogenes and other tumor 
promoters. The COX-1 enzyme of the stomach 
produces prostaglandins that ensure the natural 
mucus lining of the stomach and the integrity of 
the blood platelets. Prostaglandins synthesized by 
the COX-1 enzyme are responsible for mainte-
nance and protection of the gastrointestinal tract, 
while prostaglandins synthesized by the COX-2 
enzyme are responsible for inﬂ  ammation and pain 
(Smith and Dewitt, 1996; Williams et al. 1996a). 
When the COX enzymes are blocked, inﬂ  ammation 
is reduced, but the protective mucus lining of the 
stomach is also reduced, which can cause stomach 
upset, ulceration and bleeding from the stomach 
and intestines.
In 1991, an inducible isoform of COX which 
was subsequently named COX-2 was identiﬁ  ed 
using mitogen-stimulated chicken ﬁ  broblasts (Xie 
et al. 1991), phorbol-ester (Kujubu et al. 1991) and 
serum-stimulated murine ﬁ  broblasts (O’Banion 
et al. 1991). The COX-2 enzyme is localized in 
areas of the body that are responsible for inﬂ  am-
mation and not in the stomach. Since the COX-2 
enzyme does not play a role in the normal function 
of the stomach or intestinal tract, medications which 
selectively block COX-2 do not present the same 
risk of injuring the stomach or intestines. The rela-
tionship between cancer and inﬂ  ammation due to 
chronic infection has been suspected, but not 
proven, for many years. In 1972, Haddow showed 
the similarities between wound healing and 
carcinogenesis (Haddow A, 1972). Subsequently, 
Dvorak described tumors as wounds that do not 
heal (Dvorak, 1986). In addition to colon cancer, 
COX-2 overexpression has also been demonstrated 
in a number of premalignant and malignant condi-
tions including non-small-cell lung cancer (NSCLC), 
Barrett’s esophagus and Barrett’s adenocarcinomas 
(Wilson, 1998) and head and neck cancer (Chan 
et al. 1999).
Compelling evidence for the role of COX-2 in 
the formation of colorectal cancers has been pro-
vided by genetic studies in mice. COX-2 levels are 
markedly increased in human colorectal adenocar-
cinomas and intestinal tumors that develop in 
carcinogen-treated rats and APC Min mice 
(Kargman et al. 1995; DuBois et al. 1996; Williams 
et al. 1996b). Direct evidence that COX-2 is 
involved in colon cancer came from studies with 
knockout mice for COX-2. The study in mice 
showed that COX-2 knockout reduced both the 
size and number of intestinal polyps (Oshima et al. 
1996). In a model of mammary tumorigenesis, 
overexpression of COX-2 alone in mammary 
glands was sufﬁ  cient to induce cellular transforma-
tion which resulted in the formation of breast 
carcinomas (Liu et al. 2001).
The reason for the overexpression of COX-2 in 
cancer has not been exactly determined, because 
contrary to many other genes, the gene that codes 
for this enzyme has no mutations. COX-2 plays a 
role in angiogenesis, the growth of small blood 
vessels that allows tumors to continue to grow 
(Jones et al. 1999). Most of the actions attributed 
to COX-2 seem to be exerted by the metabolic 
products of the COX-2 pathway, prostaglandins. 
Prostaglandins synergize with mediators like his-
tamine to elicit enhanced vascular permeability 
(Tilley et al. 2001). Another important action of 
the COX-2 enzyme is inhibition of apoptosis, 
which in many cases constitutes another mecha-
nism to promote tumor cell growth. Overexpres-
sion of COX-2 is associated with increased 
proliferation and decrease in apoptosis (Tsujii and 
Dubois, 1995). The decreased cell death caused by 
COX-2 and PGE2 enhances the tumorigenic 
potential of intestinal epithelial cells (Sheng, 1998). 166
Guruswamy and Rao
Gene Regulation and Systems Biology 2008:2 
In another study, stromal production of prostacyclin 
was shown to confer an antiapoptotic effect to 
colonic epithelial cells (Cutler et al. 2003). Con-
stitutive expression of COX-2 can also lead to 
phenotypic changes which alter the metastatic 
potential of colorectal cancer. Biochemical changes 
associated with this phenotypic change includes 
the activation of membrane-type metalloproteinase-2 
(Tsujii et al. 1997).
Mechanism of COX-2 Action
in Cancer
The exact molecular mechanism of how COX-2 
causes cancer is yet to be understood. A number 
of studies suggest that the products of the COX 
pathway, prostaglandins, especially the PGE2, 
enhance cell proliferation in both normal and can-
cer cells through speciﬁ  c prostaglandin receptors 
(EP) (Yano T et al. 2002; Pai et al. 2001; Pai et al. 
2002). The EP receptors are a family within the G 
protein-coupled receptor (GPCR) superfamily of 
seven-transmembrane spanning proteins. There are 
at least nine different prostaglandin receptor forms 
reported till date (Narumiya and Fitzgerald, 2001). 
Four of these receptor subtypes bind PGE2 (EP1-
EP4), two bind PGD2 (DP1 and DP2), and the other 
receptors bind PGF2, PGI2, and TxA2 (FP, IP, and 
TP) respectively (Narumiya et al. 1999; Breyer 
et al. 2001; Hirai et al. 2001). All EP receptors are 
localized on the plasma membrane with the excep-
tion of the prostaglandin E2 receptor that is local-
ized on the nuclear membrane (Bhattacharya et al. 
1998). Although prostaglandins have been impli-
cated in functions in practically every organ, tissue 
and cell in the human body, the most prominent 
area of interest is its role in pain and inﬂ  ammation. 
As more reports emerge linking inﬂ  ammation to 
colon cancer, more studies are being carried out to 
study the effect of prostaglandins on cancer. Dis-
rupted gene targeting, such as knockouts, have 
provided valuable information into the role of 
prostaglandins and their receptors. PGE2 is widely 
considered to be the most important prostaglandin 
with regard to colorectal carcinogenesis. In colon 
cancer, large amounts of PGE2 are formed with 
levels rising dramatically as cells progress to an 
invasive phenotype (Pugh and Thomas, 1994; 
Rigas et al. 1993). A knockout of the prostaglandin 
receptor EP2 gene reduces both the size and num-
ber of intestinal tumors in APC
716 mice, similar to 
deﬁ  ciency of the COX-2 gene (Sonoshita et al. 2001). 
Akt (protein kinase B), a serine/threonine kinase, 
is as a critical enzyme in signal transduction 
pathways involved in cell proliferation, apoptosis 
and angiogenesis. Akt plays a key role in the 
regulation of cell adhesion and actin rearrangement 
(Osada et al. 1999) and PGE2 stimulation of colon 
cancer cell growth has been shown to activate 
protein kinase AKT (Castellone et al. 2005; Sheng 
et al. 2001). PGE2 is also involved in maintaining 
the stability and activation of β-catenin. Cytoplasmic 
β-catenin is involved in signal transduction and 
activation of several genes like uPAR, c-myc, 
gastrin, COX-2, MMP-7 and cyclin D1, all of which 
play important roles in the development and progres-
sion of colorectal carcinoma (Alexander, 2002). 
PGE2 increases colon cancer cell invasiveness by 
transactivating c-Met-R, which in turn increases 
tyrosine phosphorylation of β-catenin. The stabilized 
β-catenin translocates to the nucleus and triggers 
uPAR, a target gene of β-catenin, which plays a 
major role in cell migration and invasiveness (Pai 
et al. 2003; Andreasen et al. 1997). Interestingly, 
u-PAR mRNA is overexpressed in cells located at 
the tumoral-stromal interface of invasive foci of 
human colon adenocarcinomas (Pyke et al. 1991). 
Thus, PGE2 through the β-catenin-uPAR signaling 
pathway inﬂ  uences the proteolytic events occurring 
at the interface between stroma and malignant cells 
in human colon adenocarcinomas.
NFκB (Nuclear factor κB) is another important 
signaling molecule whose activation induces the 
expression of COX-2, which leads to tissue inﬂ  am-
mation (Yamamoto et al. 1995). Interestingly, the 
expression of the COX-2 gene is transcriptionally 
regulated by NFκB (D'Acquisto et al. 2002). Can-
cer cells have high levels of activated NFκB, which 
suggests that it plays an important role in malig-
nancy. NFκB is normally present in the cytoplasm 
in an inactive state, bound to its inhibitor, IkB. 
Inflammatory stimuli release NFκB from the 
inhibitor, allowing it to translocate to the nucleus 
and regulate proteins that activate the genes respon-
sible for growth, survival and the pathogenesis of 
the inﬂ  ammatory process. Some of the genes that 
are directly activated by NFκB include the cellular 
inhibitors of apoptosis, such as c-IAP1, c-IAP2 and 
IXAP, the TNF receptor associated factors TRAF1 
and TRAF2 and the antiapoptotic Bcl-2 homologue 
Mcl-1, A1/Bﬂ  -1(Wang et al. 1998; Wu et al. 1998). 
NFκB also induces the expression of cyclin D1, 
which helps in G1-to-S-phase progression by 
binding directly to its promoter (Guttridge et al. 1999). 167
Multi-target approaches in colon cancer chemoprevention
Gene Regulation and Systems Biology 2008:2 
Inhibition of NFκB activation can therefore reduce 
cyclin D1 activity and subsequent phosphorylation 
of the retinoblastoma protein. NSAIDs and corti-
costeroids can inhibit the activation of NFκB at 
different points in the signaling pathway. The 
inhibitory effects of aspirin result from the inhibi-
tion of ATP-binding to IKKβ, which reduces the 
phosphorylation of Iκ Bα and thus prevents its 
degradation (Yin, 1998). Several NSAIDs have also 
been shown to inhibit NFκB activation. For exam-
ple, ibuprofen inhibits NFκB activation, as well as 
COX-2 expression and PGE2 production in murine 
macrophages (Lo et al. 1998). Another NSAID, 
sulindac, has been shown to decrease IKKβ kinase 
activity and, thereby inhibit NFκB activation 
(Yamamoto et al. 1999). Although it is clear that 
NFκB induces COX-2 expression, it is not yet 
known if COX-2 also positively regulates NFκB 
levels. A number of kinases, such as AKT and MEK 
kinases, activate IKK. AKT activates p-21 activated 
kinase (PAK1) and that stimulates the nuclear 
translocation of the NFκB subunit, p65 (Frost et al. 
2000; Tang et al. 2000). Neither COX-2 nor its 
metabolite PGE2 activates NFκB directly. Since 
COX-2 and PGE2 activate AKT, and AKT is known 
to play a major role in NFκB activation, we can 
assume that COX-2 exerts its effect on NFκB 
through AKT. In a different scenario, COX-2 may 
also be regulating the activity of NFκB through 
proteins other than AKT. In spite of the above 
described mechanisms, the complete picture of how 
COX-2 and its proinﬂ  ammatory metabolite PGE2 
enhance colon cancer progression remains poorly 
understood. The schematic representation of COX-2 
signaling mechanism is shown in Figure 1.
Because COX-2 is responsible for the increased 
PGE2 production in cancer, the inhibition of COX-2 
activity is critical for colon cancer chemopreven-
tion. Non-steroidal anti-inflammatory drugs 
(NSAIDs) block COX enzymes and reduce pros-
taglandins throughout the body. As a consequence, 
inﬂ  ammation, pain and fever are reduced. Several 
studies have showed that COX-2-speciﬁ  c and non-
speciﬁ  c NSAIDs induce apoptosis in a number of 
different cancers like gastric and lung cancer cells 
(Cao et al. 2002; Lin et al. 2002; Howe et al. 2002). 
Since NSAIDs block both COX-1 and COX-2, 
prostaglandins produced by COX-1 are also 
blocked. Therefore, a relatively new class of drugs 
called selective COX-2 inhibitors, such as valde-
coxib, celecoxib and rofecoxib were introduced 
which specifically block the COX-2 enzyme. 
Celecoxib has been shown to inhibit aberrant crypt 
foci (ACF) incidence and multiplicity in AOM 
induced mouse carcinogenesis model (Reddy et al. 
1996), as well as tumor incidence, multiplicity and 
volume (Reddy et al. 2000). Blocking the COX-2 
enzyme impedes the production of the prostaglan-
dins which cause pain, inﬂ  ammation and cancer.
HMG-CoA Reductase and Cancer
HMG-CoA reductase (or 3-hydroxy-3-methyl-
glutaryl-CoA reductase or HMGR) is the ﬁ  rst 
enzyme of the HMG-CoA reductase pathway, the 
metabolic pathway that produces cholesterol. 
Cholesterol, a major constituent of the eukaryotic 
cell membranes regulates the physical state of the 
phospholipid bilayer, affects the activity of several 
membrane proteins and is the precursor for steroid 
hormones and bile acids. Cholesterol also plays a 
crucial role in the formation of membrane 
microdomains, such as lipid rafts and caveolae. 
In addition to synthesizing cholesterol, HMG-
CoA reductase also produces a number of non-
sterol products. One of the first products 
synthesized by the HMG-CoA reductase is 
mevalonate. Mevalonate is converted to farnesyl 
diphosphate, geranylgeranyl diphosphate which 
are two important isoprenoids essential for the 
post-translational modiﬁ  cation and biological 
activity of diverse array of proteins that have 
roles in cell shape, motility, cell division and 
survival. Inhibition of HMG CoA reductase will 
suppress the synthesis of isoprenoid moieties 
required for the post-translational modiﬁ  cation 
of several important proteins like Ras, Rho, and 
lamin B and therefore offers a novel target for 
cancer chemoprevention.
Caveolae in Cancer Cell Signaling
A wide variety of mammalian cells have special-
ized plasma membrane microdomains that are 
characterized by their high content of spingolipids 
and cholesterol (Okamoto et al. 1998). These 
regions, called lipid domains, are more rigid than 
the rest of the cell membrane because of cholesterol. 
These cholesterol rich regions can be isolated from 
the rest of the plasma membrane because they are 
resistant to dispersion by non-ionic detergents and 
are commonly referred as caveolae. Caveolae are 
cholesterol rich ﬂ  ask shaped invaginations present 
on the plasma membrane. Caveolae is known to 
be involved in several cellular events, including 168
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cholesterol trafﬁ  cking and coordinating signaling 
events (Uittenbogaard et al. 1998). Caveolae and 
lipid rafts may serve as a way to cross-link certain 
pathways in the microdomains of the plasma 
membrane. The major component of caveolae is 
the membrane protein caveolin. There are three 
kinds of caveolin, named caveolin-1, caveolin-2 
and caveolin-3 (Smart et al. 1999). All three 
caveolins are structurally similar and have hairpin 
loops criss-crossing the membrane. Caveolin-1 is 
the major component molecule of caveolae 
(Rothberg et al. 1992) and plays an important role 
in tumorigenesis and cancer progression. While, 
the expression of caveolin-1 is elevated in a majority 
of the colon adenocarcinomas, the expression of 
caveolin-2 is undetectable in either normal colo-
nocytes, adenomas, or carcinomas (Fine et al. 
2001; Patlolla et al. 2004). Caveolin-3 is not 
expressed in the colon and is restricted to muscu-
lar tissue (Tang et al. 1996). The identiﬁ  cation of 
caveolins as the major proteins of caveolae has 
sparked research into the role and functions of 
caveolae. Caveolin-1 plays a critical role in orga-
nizing signaling machinery at the cell surface. The 
correct arrangement of signaling molecules in these 
domains is vital for communication inside the cell 
and is dependent on proper levels of cholesterol. 
Caveolin-1 contains a scaffolding domain to which 
a number of signaling molecules like G-protein-
coupled receptors, heterotrimeric G proteins, 
receptor tyrosine kinases, components of the Ras-
mitogen-activated protein (MAP) kinase pathway, 
Src-like kinases, protein kinase C (PKC), nitric 
oxide synthase (NOS), H-Ras and eNOS are bound 
and concentrated (Anderson, 1993; Anderson, 
1998; Li et al. 1995; Huang et al. 1997). Caveolin-1 
itself may positively or negatively regulate 
signaling either through direct or indirect protein—
protein interactions with resident caveolae proteins. 
The 20-amino acid membrane proximal region 
of the cytosolic amino-terminal domain of 
caveolin-1 is sufﬁ  cient to mediate these interac-
tions (Couet et al. 1997).
Caveolae plays pivotal roles in intracellular 
signal transduction, angiogenesis and tumor inva-
sion (Simons and Ikonen, 1997; Simons and 
Toomre, 2000). Tumor cell invasion is an extremely 
important factor for the formation of solid tumors 
and necessary for its spread to different organs. 
The high mortality associated with colorectal 
cancer is related to its ability to spread beyond the 
large intestine and invade distant sites. Angiogenesis 
is the formation of new capillaries characterized 
by the proliferation, migration and remodeling of 
endothelial cells and their progenitors. The pro-
gressive growth and spread of tumors has been 
shown to be angiogenesis-dependent and a role for 
caveolin-1 in this process has been implicated 
(Woodman et al. 2003). For example, overexpres-
sion of caveolin-1 signiﬁ  cantly enhances endothe-
lial cell differentiation into tube-like structures and 
downregulation of caveolin-1 protein levels using 
antisense oligonucleotides reduced the ability of 
the endothelial cells to form an organized network 
(Liu et al. 2002; Griffoni et al. 2000). Similarly, 
tumor angiogenesis was reduced in caveolin
–/– mice 
implanted with B16 melanoma cells (Woodman 
et al. 2003). There is a signiﬁ  cantly higher percent-
age of tumor associated endothelial cells (TAEC) 
in cav-1 positive tumors than in cav-1 negative 
tumors (Yang et al. 2007). Caveolin-1 is also an 
important regulator of eNOS signaling in endothe-
lial cells. NO plays a major role in angiogenesis 
(Takahashi et al. 1997) acting downstream of vas-
cular endothelial growth factor (VEGF). Cav−/− 
mice do not develop a functional vasculature and 
the effects observed in Cav−/− mice are similar to 
the effects of the NOS inhibitor L-NAME admin-
istered to Cav+/+ mice (Sonveaux et al. 2004). 
These results suggest that caveolin-1 is important 
for the organization of a new capillary network.
The concentration of caveolae near the intercel-
lular junctions suggests that certain junctional 
molecules may colocalize with caveolin-1. 
Caveolin-1 has been shown to play a role in signal 
transduction mediated by integrin signaling 
(Totsukawa et al. 2000; Giancotti et al. 1999). Cell 
migration depends on integrins that attach cells to 
their substratum and regulate the organization of 
the cytoskeleton. The tyrosine phosphorylated 
form of caveolin-1 colocalizes with focal adhesions, 
suggesting a role for caveolin-1 in migration. αVβ3 
integrins were identified to colocalize with 
PI3-K/caveolin-1 complexes (Sedding et al. 2005). 
The integrin-caveolin-1 complex triggers the 
mitogen-activated protein kinase pathway, which 
controls progression through the cell cycle. 
Caveolin-1 mediated integrin signaling thus plays 
an important role in organizing cytoskeleton, cell 
migration and proliferation.
The overexpression or the targeted disruption 
of caveolin-1 has provided signiﬁ  cant insights into 
the roles of the caveolin-1 and caveolae. Caveolin-1 
constitutes a key switch in tumor development 169
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through its association of various signaling mol-
ecules. Disruption of membrane microdomains, 
like caveolae, with drugs like statins which seques-
ter cholesterol will affect several signaling path-
ways associated with caveolae. Statins by blocking 
cholesterol synthesis leads to the perturbation of 
the lipid phase of the cell membrane and thus 
enhances the potenticity of anticancer drugs. The 
membrane mediated action of statins through 
modulation of membrane ﬂ  uidity is also likely to 
play an important role in anticancer action and its 
ability to reverse multidrug resistance.
Cholesterol and Lipid Bodies
One important aspect of cholesterol regulation is 
intracellular cholesterol storage in lipid storage 
organelles, called lipid droplets or lipid bodies. 
Mammalian lipid bodies are spherical structures 
containing a mixture of triglycerides or cholesterol 
esters encased in a thin phospholipid membrane 
(Martin and Parton, 2006). They also contain a 
pool of proteins with a wide range of biochemical 
activities. Only a few of these proteins have been 
identiﬁ  ed, and very little is known about their 
structural properties and functions. Lipid bodies 
shufﬂ  e components around the cell, store energy 
in the form of neutral lipids and possibly maintain 
the many membranes of the cell. High concentra-
tions of lipid bodies develop in cells associated 
with inﬂ  ammation reactions (Coimbra et al. 1971; 
Weinstein, 1980). Various cytokines and pro-
inﬂ  ammatory stimuli trigger the synthesis of COX-2 
leading to increased formation of eicosanoids. 
There is increasing evidence that speciﬁ  c compart-
mentalization of eicosanoid formation within cells 
may relate to the different autocrine and paracrine 
functions of eicosanoids (Serhan, 1996; Smith et al. 
1996). Lipid bodies are sites of intracellular local-
ization of COX-2 (Dvorak et al. 1994; Bozza et al. 
1997a), as well as repositories of esteriﬁ  ed arachi-
donates (Weller et al. 1991). Lipid bodies serve as 
novel putative sites for eicosanoid biosynthesis in 
cells involved in inﬂ  ammation (Bozza et al. 1996; 
Bozza et al. 1997b). Caveolin-1 plays an important 
role in the modulation of lipolysis and lipid drop-
let formation (Cohen et al. 2004). In support of 
this, Caveolin-1 has been shown to be redirected 
from the plasmamembrane caveolae to intracellular 
lipid droplets (Razani et al. 2002). Caveolin-1 is 
also important for maintaining the architecture of 
the lipid droplet cortex. For example, caveolin-1 
null perigonadal adipocytes exhibit dramatically 
altered lipid droplet cortex compared to normal 
adipocytes (Cohen et al. 2004). Since lipid bodies 
contain cholesterol, COX-2 as well as caveolin-1, 
statins will be useful in disrupting the membrane 
integrity of the lipid bodies while COX-2 inhibitors 
can be used to block the activity of the COX-2 
enzyme.
Prenylation and Cell Signaling
Although the beneﬁ  cial effects of statins result 
from their cholesterol lowering properties that lead 
to disruption of membrane microdomains and pos-
sibly lipid bodies, recent observations also suggest 
that statins exhibit effects independent of their 
cholesterol-lowering properties. In addition to 
synthesizing cholesterol, the HMG-CoA reductase 
pathway also produces several biological interme-
diates, called isoprenoids, which include geranyl 
pyrophosphate and farnesyl pyrophosphate. Iso-
prenoids serve as important lipid attachments to 
the C-terminal cysteine’s of proteins such as small 
GTP binding proteins, which are implicated in 
intracellular signaling. Prenylated proteins play a 
central role in signaling an array of cellular 
responses, such as cell division, motility and apop-
tosis (Table 1). Prenylation reactions are catalyzed 
by protein farnesyltransferase (FTase) and protein 
geranylgeranyltransferases (GGTases), respec-
tively. Prenylation promotes the membrane asso-
ciation of the target protein (Casey and Seabra, 
1996). The covalent addition of an isoprenoid to 
the carboxyl terminal cysteine changes the polarity 
of the protein and enables its binding to mem-
branes. The isoprenoid geranylgeranylpyrophos-
phate activates a group of Rho, Rac and cdc42 
proteins (Adamson et al. 1992). These proteins 
exert a wide range of effects that include cell pro-
liferation, migration and increasing oxidation 
stress. A few important examples of farnesylated 
proteins include Ras and lamin B. Tumor cells 
exhibit a greater need for isoprenoids than normal 
cells (Buchwald, 1992). Tumor cells are, therefore, 
associated with a sterol feedback resistant 
HMG-CoA reductase activity, which ensures a 
steady pool of sterologenic pathway intermediates 
(Elson et al. 1999).
The family of proteins known as Ras plays a 
central role in integrating the regulatory signals 
that govern the cell cycle and proliferation (White 
et al. 1995). Defects in the Ras-Raf pathway can 170
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result in cancerous growth. Mutant Ras genes were 
among the first oncogenes identified for their 
ability to transform cells to a cancerous phenotype. 
The highest incidences of Ras mutations are found 
in cancers of the pancreas (80%) and colon (50%) 
(Duursma et al. 2003; Minamoto et al. 2000). 
Mutations in one of three genes (H, N or K-Ras) 
encoding Ras proteins are associated with increased 
cell proliferation and are found in an estimated 
30%–40% of all human cancers. The Ras-Raf 
pathway is used by cells to transmit signals from 
the cell surface to the nucleus. Such signals direct 
cells to divide, differentiate or even undergo 
apoptosis. The Ras protein usually behaves as a 
relay switch in the signal pathway that triggers the 
cell to divide. In the absence of stimulus, the Ras 
protein remains in the “off” position. In response 
to external stimuli, Ras activates the cell-signaling 
pathways. A mutated Ras protein, however, is like 
a switch stuck in the “on” position. It continuously 
signals the cell to divide when the cycle should 
have actually been turned off (Gibbs et al. 1996). 
Irrespective of whether it is normal or a mutant, 
the newly formed Ras molecules are functionally 
immature. Precursor Ras genes must undergo 
biochemical modiﬁ  cation called farnesylation to 
become mature, active versions. The farnesylation 
of the Ras proteins enable it to attach to the inner 
surface of the cells outer membrane where they 
can interact with other cellular proteins and stimu-
late cell growth. Statins block the HMG-COA 
reductase enzyme, which depletes cells of farnesyl 
pyrophosphate. Although the levels of total Ras do 
not decrease, the amount of farnesylated Ras 
decreases, which in turn, leads to reduced cell 
division (Hohl et al. 1995).
Prenylation also plays an important role in 
stimulating the development, angiogenesis and 
metastasis of cells in response to changes in the 
extracellular environment. Rho GTPases play a 
central role in diverse biological processes, such 
as actin cytoskeleton organization, microtubule 
dynamics, gene transcription, oncogenic transfor-
mation, cell cycle progression, adhesion and 
malignant transformation (Hall, 1998; Linda and 
Crislyn, 1997). The Rho family of proteins is 
made up of three subfamilies, Rho, Rac and 
Cdc42. The Rho subfamily regulates the forma-
tion of stress ﬁ  bers and focal adhesions within 
cells, while the Rac subfamily regulates the for-
mation of lamellipodia and membrane rufﬂ  ing, 
whereas the Cdc42 subfamily regulates formation 
of ﬁ  lopodia (Jaffe and Hall, 2005; Burridge and 
Wennerberg, 2004). Elevated levels of Rho-GTP 
have been observed in several human cancers. A 
decrease in Rho activities has a negative impact 
on cell growth, suggesting that active Rho pro-
motes tumor cell proliferation (Khosravi-Far et al. 
1995). Rho proteins cycle between an active GTP-
bound state and an inactive GDP-bound state 
(Etienne-Manneville and Hall, 2002). Their acti-
vation state is controlled by regulatory proteins, 
such as guanine exchange factors (GEFs), which 
catalyze the exchange of GDP for GTP, thereby 
activating Rho (Etienne-Manneville and Hall, 
2002). In contrast, Guanine dissociation inhibitors 
(GDIs), which inhibit the release of GDP and 
GTPase activating proteins (GAPs), increases the 
rate at which Rho hydrolyzes GTP keeps the Rho 
inactivated. Rho-associated serine-threonine 
protein kinase (ROCK), one of the best character-
ized downstream effectors of Rho, is activated 
when it selectively binds to the active GTP-bound 
form of Rho. Activated ROCK interacts with the 
actin cytoskeleton to promote stress-fiber 
formation and assembly of focal contacts (Kamai 
et al. 2003). Cancer cell migration is central to 
the process of metastasis. This involves the 
Table 1. List of prenylated proteins.
Protein   Type of modiﬁ  cation
LaminB (Mitotic spindle)  Farnesylation
H-Ras (Signal transduction)  Farnesylation
K-Ras (Signal transduction)  Farnesylation/Geranylgeranylation
Cdc42 (Cell cycle)  Geranylgeranylation
Rac (Signal transduction)  Geranylgeranylation
Rab (Vesicle transport)  Geranylgeranylation
Rho (Signal transduction/Cytoskeleton)  Geranylgeranylation
γ-subunit of G proteins  Geranylgeranylation
Rhodopsin kinase (Visual cycle)  Farnesylation171
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rearrangement of the actin cytoskeleton. Since 
the Rho/ROCK pathway takes part in cancer 
progression by regulating actin cytoskeleton 
reorganization and cell migration, statins by 
blocking Rho prenylation can inhibit tumor 
growth and metastasis.
The nuclear architecture is deﬁ  ned by a spe-
cialized cytoskeleton, called the nuclear lamina. 
Nuclear lamina is formed by the type V interme-
diate ﬁ  lament proteins, the lamins (Aebi et al. 
1986). Lamin B, along with Lamin A and C, 
together form a complex meshwork of tetrago-
nally organized 10 nm ﬁ  laments underneath the 
inner nuclear membrane (Stuurman et al. 1998). 
B-type lamins are ubiquitously expressed during 
development and every cell expresses at least one 
type of lamin B. There are two B-type lamins, B1 
and B2, expressed from different genes. B type 
lamins are essential, while the A-type lamins are 
believed to be non-essential and are only 
expressed in differentiated cells (Foisner, 2001). 
B-type lamins contain a stable C-terminal farne-
syl modiﬁ  cation, which is important for targeting 
and anchoring the protein to the inner nuclear 
membrane (Firmbach-Kraft, and Stick, 1995). 
The ﬁ  rst direct connection between lamin B and 
chromatin remodeling has been demonstrated by 
the discovery of the inner nuclear membrane 
protein, RING ﬁ  nger-binding protein (RFBP) 
(Mansharamani et al. 2001). RFBP binds to lamin B 
and interacts directly with the RUSH protein to 
remodel chromatin complexes. The karyoskeleton 
formed by the lamin proteins serves to organize 
protein complexes within the nucleus and their 
interactions with chromatin, as well as providing 
structural support to the nucleus (Gruenbaum 
et al. 2005; Taddei et al. 2004). In doing so, lamins 
are involved in a range of nuclear functions, 
including regulation of gene expression and DNA 
replication, although the molecular details of 
these functions are still to be elucidated. Lamin B 
depletion by RNA interference in C. elegans is 
lethal and associated with a number of phenotypic 
changes, such as irregularly organized nuclear 
pore complexes, irregularities in nuclear shape 
and defects in chromosomal organization and 
segregation (Liu et al. 2000). A recent study 
shows that lamin B functions in mitotic spindle 
assembly through a process that involves the GTP 
bound form of the small GTPase Ran. Lamin B 
is essential for the formation of the mitotic matrix 
that binds together a number of spindle assembly 
factors. Lamin B, therefore, by forming the 
mitotic spindle matrix, promotes microtubule 
assembly and organization. Blocking the prenyl-
ation of lamin B with drugs like statins will pre-
vent their entry into nucleus and ability of the 
cancer cells to divide.
Although statins have a proven effect of reduc-
ing serum LDL concentration, several lines of 
evidence suggest that statins exhibit some 
interesting effects that cannot be explained by 
lowering of the LDL levels alone. While the effect 
of statins on caveolae disruption and caveolin-1 
function may be related to its ability to block 
cholesterol formation, the effect of statins on 
proteins like lamin B, Ras and Rho is due to the 
unavailability of cholesterol biosynthetic pathway 
intermediates called isorenoids. HMG-CoA 
reductase inhibitors, such as statins, block the ﬁ  rst 
step in the cholesterol biosynthetic pathway. 
Therefore, by using statins, the end product 
cholesterol, as well as the production of several 
intermediates in the cholesterol biosynthetic 
pathway is inhibited. As the synthesis of 
mevalonate by the enzyme HMG-CoA reductase 
is a committed step in both, cholesterol and prenyl 
lipid biosynthesis pathways, the use of HMG-CoA 
reductase inhibitors, such as the statins, could be 
used to inhibit prenylation. Ras, both mutant and 
wild type, must be farnesylated for proper 
processing, subcellular localization and biological 
activity. Interestingly, statins ability to block the 
prenylation of several important proteins, like Ras 
and Rho is important in regulating the growth of 
cancer cells. The pleiotropic effects of statins as 
discussed earlier, therefore, represent an area of 
great interest in the prevention and therapy of 
cancer. The schematic representation of COX-2 
and HMG-CoA reductase signaling mechanism 
and the cross-talk between these two pathways is 
shown in Figure 2.
Conclusion
In principle, targeting a single gene should be 
sufficient to induce apoptosis or decrease 
proliferation effectively in cancer cells. 
However, considering that several genes belong-
ing to different metabolic pathways are upregu-
lated, the traditional single-drug, single-target 
approach should be replaced by the multi-drug, 
multiple-target approach. The aim of the present 
review was to provide the knowledge of how a 172
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combination of COX-2 inhibitors and HMG-
CoA reductase inhibitors can be used to block 
various signaling cascades within the context 
of COX-2 and HMG-CoA reductase pathways. 
With regard to COX-2 inhibitors, recent 
evidence indicates that patients treated with 
selective COX-2 inhibitors exhibit slightly 
increased risk of cardiovascular problems such 
as heart attacks and strokes. COX-2 reduces 
prostacyclin formation by tipping the balance 
of prostacyclin/thromboxane in favor of throm-
boxane, a prothrombotic eicosanoid. The 
increased levels of thromboxane, accompanied 
by a decrease in prostacyclin can lead to the 
development of thrombotic cardiovascular 
events (Bing and Lomnicka, 2002). This may 
be prevented by the addition of a nitric oxide 
donor to the parent compound such as aspirin 
or pravastatin through chemical spacers, such 
as aliphatic, aromatic, or a heterocyclic chain. 
This approach has led to the synthesis of several 
new drugs such as NO-aspirin, NO-naproxen 
and more recently NO-pravastatin, which are 
not only more effective than the parent 
compound, but also exhibit a better safety proﬁ  le. 
The possibilities described above makes it an 
attractive option to test several anti-cancer drug 
combinations.
Figure 2. COX-2 and HMG-COA reductase pathway and its associated signaling molecules.
HMG-R inhibitors block the conversion of 3-HMG-CoA to mevalonate, preventing the formation of Farnesyl-PP and Geranylgeranyl-PP and 
subsequently, prenylation of Ras, Raf, Rho and lamin B. HMG-R inhibitors also block cholesterol, thereby disrupting Cav-1 associated 
signaling and lipid bodies. COX-2 activates β-Catenin, AKT and subsequently STAT3 and NFκB. STAT3, β-Catenin and NFκB then translo-
cate to the nucleus and transcribe genes involved in survival and proliferation. COX-2 also promotes lipid body formation.
Abbreviations: NFκB: nuclear factor κB; Cyc D1: Cyclin D1; B-Cat: β-catenin; ERK: extracellular regulated kinase; AKT: also known as 
protein kinase B (PKB); STAT3: signal trandsducer and activator of transcription; Cav-1: caveolin-1; EGFR: epidermal growth factor receptor; 
IGFR: insulin growth factor receptor; TM: transmembrane protein; LB: lipid bodies; PL: phospho lipids; AA: arachidonic acid; COX-2: 
cyclooxygenase 2; VEGF: vascular endothelial growth factor; iNOS: inducible nitric oxide synthase; ilk: integrin linked kinase; ROCK: Rho 
kinase: MEK: MAP kinase.173
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